JUBLPHARMA - Swing Trade Analysis with AI Signals
Back to List📊 Swing Trade Rating: 3.3
| Stock Code | JUBLPHARMA | Market Cap | 15,530 Cr. | Current Price | 973 ₹ | High / Low | 1,250 ₹ |
| Stock P/E | 495 | Book Value | 145 ₹ | Dividend Yield | 0.51 % | ROCE | 1.80 % |
| ROE | 1.35 % | Face Value | 1.00 ₹ | DMA 50 | 961 ₹ | DMA 200 | 981 ₹ |
| Chg in FII Hold | -0.06 % | Chg in DII Hold | 0.40 % | PAT Qtr | 65.7 Cr. | PAT Prev Qtr | 6.60 Cr. |
| RSI | 49.8 | MACD | 3.41 | Volume | 83,684 | Avg Vol 1Wk | 88,005 |
| Low price | 784 ₹ | High price | 1,250 ₹ | PEG Ratio | -34.9 | Debt to equity | 0.02 |
| 52w Index | 40.7 % | Qtr Profit Var | 7,200 % | EPS | 3.97 ₹ | Industry PE | 32.1 |
Jubilant Pharmova (JUBLPHARMA) shows weak-to-moderate potential for swing trading. The current price of ₹973 is near the 50 DMA (₹961) and 200 DMA (₹981), reflecting consolidation. RSI at 49.8 suggests neutral momentum, while MACD at 3.41 indicates mild bullishness. Fundamentals are poor with ROCE at 1.80% and ROE at 1.35%. EPS of ₹3.97 and an extremely high P/E of 495 compared to industry PE of 32.1 highlight severe overvaluation. Debt-to-equity at 0.02 is very low, showing minimal leverage risk. Quarterly PAT surged to ₹65.7 Cr. from ₹6.60 Cr., but PEG ratio (-34.9) indicates poor growth valuation. Overall, the stock is technically stable but fundamentally weak, making it a cautious swing trade candidate.
✅ Optimal Entry Price: Around ₹940–₹960 (near DMA support)
📈 Exit Strategy (if already holding): Consider exiting near ₹1,000–₹1,020 (resistance zone).
---
🌟 Positive
- 📉 Very low [debt-to-equity](ca://s?q=Debt_to_equity_ratio) ratio of 0.02 ensures minimal leverage risk.
- 📈 Quarterly PAT surged from ₹6.60 Cr. to ₹65.7 Cr. (+7,200%).
- 💡 Domestic institutional investors increased holdings (+0.40%).
- 📊 MACD at 3.41 shows short-term bullish momentum.
⚠️ Limitation
- 📉 Extremely high [P/E ratio](ca://s?q=Explain_PE_ratio) of 495 vs industry PE of 32.1 suggests severe overvaluation.
- 📊 Weak [ROCE](ca://s?q=Explain_ROCE) (1.80%) and [ROE](ca://s?q=Explain_ROE) (1.35%).
- 📉 EPS of ₹3.97 is very low.
- 📊 PEG ratio of -34.9 indicates poor valuation relative to growth.
📰 Company Negative News
- 📉 Stock corrected from 52-week high of ₹1,250.
- 📊 FII holdings decreased (-0.06%), showing reduced foreign investor confidence.
📢 Company Positive News
- 💡 Quarterly PAT improved significantly (₹6.60 Cr. → ₹65.7 Cr.).
- 📈 Domestic institutional inflows (+0.40%) support sentiment.
- 📊 Stock rebounded from 52-week low of ₹784.
🏭 Industry
- 📊 Industry PE is 32.1 vs JUBLPHARMA’s 495 → highly overvalued compared to peers.
- 🌐 Pharma sector benefits from healthcare demand but faces margin volatility and regulatory risks.
✅ Conclusion
JUBLPHARMA is a weak swing trade candidate with entry near ₹940–₹960 and exit around ₹1,000–₹1,020. Fundamentals remain poor with low profitability and extreme valuation, though short-term momentum and institutional support provide limited trading opportunities. Traders should remain cautious and use strict stop-loss strategies.
Would you like me to expand this into a peer comparison or a broader pharma sector outlook to refine swing trade opportunities?